American CryoStem Corporation - CRYO STOCK NEWS

American CryoStem Corporation (OTC PINK:CRYO) has announced the successful completion of participant recruitment for its Phase I Clinical Trial targeting Post-Concussion Syndrome. Conducted at BioSolutions Clinical Research Center, the study focuses on ATCELL™ therapy, which utilizes autologous mesenchymal stem cells. Treatments are scheduled to commence in January 2022. With an annual cost of traumatic brain injuries in the U.S. estimated at $48.3 billion, the study aims to address significant unmet medical needs in this area.

American CryoStem Corporation (OTC PINK:CRYO) has completed its Phase I clinical protocol design aimed at treating Long COVID. They plan to file an FDA Phase I IND application in collaboration with a major US medical center in Q1 2022. Long COVID patients can suffer from various prolonged symptoms affecting multiple organ systems. Current estimates indicate that up to 30% of COVID-19 survivors experience lingering health issues. The upcoming trial will evaluate the safety and tolerability of CryoStem's proprietary ATCell® therapy, focusing on developing an effective treatment for Long COVID.

American CryoStem Corporation (OTC PINK:CRYO) has appointed John Schwartz, PhD to its Scientific and Medical Advisory Board. Dr. Schwartz, a biochemistry expert with over 30 years of experience in biopharmaceuticals, is expected to enhance the company's strategic direction leading to successful Biologic License Applications. His prior achievements include guiding AcuityBio to acquisition and mentoring numerous life sciences startups. CEO John Arnone highlighted Dr. Schwartz's expertise as critical for advancing the company's innovative stem cell technology platform, aimed at developing groundbreaking therapies for serious illnesses.

American CryoStem Corporation (OTC PINK:CRYO) has developed a new standardized wound healing protocol in collaboration with Advanced Regenerative Associates. This protocol utilizes human tissue and cell products while complying with FDA exemptions. The initial study, involving 10 patients in New Jersey, aims to validate the treatment's effectiveness for chronic wounds, which affect over 6.5 million people in the U.S. The company plans to collect data for future FDA-approved advanced wound care therapies.

American CryoStem Corporation (OTC PINK:CRYO) announced a share exchange agreement with ACS Global, Inc., exchanging 20,000,000 common shares for 1,000,000 shares of preferred stock. The terms of the preferred stock were not disclosed. Management believes this transaction will benefit stakeholders and support ongoing clinical trials and business plans. Established in 2008, CryoStem specializes in autologous mesenchymal stem cell therapies with a focus on personalized medicine and a diverse pipeline targeting various medical needs.

American CryoStem Corporation (OTC PINK:CRYO) announced a Letter of Intent with Advanced Regenerative Associates to develop a cell-based wound covering treatment targeting non-healing wounds, skin ulcers, and limb ischemia due to diabetes.

The partnership aims to enhance dermal regeneration using American CryoStem's ATCELL™ products. The diabetic foot ulcer treatment market is projected to reach USD 11.09 billion by 2026. CEO John Arnone emphasized the potential for substantial revenue from new products addressing large markets with unmet clinical needs.

American CryoStem Corporation (OTC: CRYO) has initiated patient biomaterial processing for its FDA-approved IND Phase I Clinical Trial targeting Post-Concussion Syndrome (PCS)ATCell™. The company has successfully screened five participants, marking progress in addressing significant unmet medical needs associated with traumatic brain injuries, estimated to cost the U.S. $48.3 billion annually.

American CryoStem Corporation (OTC PINK:CRYO) has entered into a collaborative agreement with BioTherapeutic Labs Corp. (BTL) to enhance cell recovery from umbilical cords. This partnership aims to support the development of advanced regenerative therapies using CRYO's autologous mesenchymal stem cells and BTL's umbilical cord products. The collaboration is expected to lead to substantial sales and licensing revenue while improving treatment options for patients with limited therapies. Both companies focus on improving immune response modulation and tissue regeneration for various medical conditions.

American CryoStem Corporation (OTC PINK:CRYO) has initiated patient recruitment for its IND Phase I Clinical Trial focused on post-concussion syndrome (PCS). The ATCELL™ trial will utilize autologous mesenchymal stem cell infusion therapy. Dr. Rand McClain joins the principal investigators as a sub-investigator. This trial addresses the substantial $48.3 billion annual cost of traumatic brain injuries in the U.S., with significant implications for healthcare. The clinical trial will be managed by BioSolutions Clinical Research Center in California.